Aprea Therapeutics to Present at Oppenheimer’s 33rd Annual Healthcare Conference
Aprea Therapeutics, a biopharmaceutical company focused on cancer therapeutics, announced that CEO Oren Gilad will present at the Oppenheimer 33rd Annual Healthcare Conference on March 14, 2023, at 10:00 a.m. ET. The presentation will provide a corporate overview and will be accessible via a live webcast on the company's website, followed by a replay available for 90 days. Aprea is developing innovative drugs targeting DNA damage response pathways, with its lead program being ATRN-119, aimed at treating solid tumors. The company emphasizes its commitment to disclosing material information via its investor relations platform.
- None.
- None.
DOYLESTOWN, Pa., March 07, 2023 (GLOBE NEWSWIRE) -- Aprea Therapeutics, Inc. (Nasdaq: APRE) (“Aprea”, or the “Company”), a biopharmaceutical company focused on developing novel synthetic lethality-based cancer therapeutics targeting DNA damage response (DDR) pathways, today announced that Oren Gilad, Ph.D., President and Chief Executive Officer, will present a corporate overview and host 1x1 meetings at the Oppenheimer 33rd Annual Healthcare Conference, being held online from March 14-16, 2023.
Oppenheimer 33rd Annual Healthcare Conference
Date: Tuesday, March 14, 2023
Time: 10:00 a.m. ET
A live webcast of the presentation will be available in the “Upcoming Events” section under the “News and Events” tab of the Company’s website (www.aprea.com). A replay of the webcast will be archived on the Company’s website for 90 days following the presentation.
About Aprea Therapeutics, Inc.
Aprea Therapeutics, Inc. is a biopharmaceutical company headquartered in Doylestown, Pennsylvania, focused on developing and commercializing novel synthetic lethality-based cancer therapeutics targeting a critical pathway and some of the most central targets in DDR and cancer progression. The Company’s lead program is ATRN-119, a clinical-stage small molecule ATR inhibitor being developed for solid tumor indications. Our WEE1inhibitor is being advanced to IND submission. For more information, please visit the company website at www.aprea.com.
The Company may use, and intends to use, its investor relations website at https://ir.aprea.com/ as a means of disclosing material nonpublic information and for complying with its disclosure obligations under Regulation FD.
Forward Looking Statement
Certain information contained in this press release includes “forward-looking statements”, within the meaning of Section 27A of the Securities Act of 1933, as amended, and Section 21E of the Securities Exchange Act of 1934, as amended, related to our study analyses, clinical trials, regulatory submissions, and projected cash position. We may, in some cases use terms such as “future,” “predicts,” “believes,” “potential,” “continue,” “anticipates,” “estimates,” “expects,” “plans,” “intends,” “targeting,” “confidence,” “may,” “could,” “might,” “likely,” “will,” “should” or other words that convey uncertainty of the future events or outcomes to identify these forward-looking statements. Our forward-looking statements are based on current beliefs and expectations of our management team that involve risks, potential changes in circumstances, assumptions, and uncertainties. Any or all of the forward-looking statements may turn out to be wrong or be affected by inaccurate assumptions we might make or by known or unknown risks and uncertainties. These forward-looking statements are subject to risks and uncertainties including risks related to the success and timing of our clinical trials or other studies, risks associated with the coronavirus pandemic and the other risks set forth in our filings with the U.S. Securities and Exchange Commission. For all these reasons, actual results and developments could be materially different from those expressed in or implied by our forward-looking statements. You are cautioned not to place undue reliance on these forward-looking statements, which are made only as of the date of this press release. We undertake no obligation to publicly update such forward-looking statements to reflect subsequent events or circumstances.
Source: Aprea Therapeutics, Inc.
Investors and Media:
aprea@argotpartners.com
212-600-1902
FAQ
When is Aprea Therapeutics presenting at the Oppenheimer Annual Healthcare Conference?
What is the focus of Aprea Therapeutics?
How can I watch the Aprea Therapeutics presentation?
What is Aprea's lead program?
Will there be a replay of the Aprea Therapeutics presentation?
